Zhangzhou Pientzehuang Pharmaceutical Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jin Ming Huang

Geschäftsführender

CN¥601.7k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.9yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.9yrs

Jüngste Management Updates

Recent updates

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

May 27

Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price

Feb 28

Geschäftsführer

Jin Ming Huang (58 yo)

4.9yrs

Amtszeit

CN¥601,700

Vergütung

Mr. Jin Ming Huang is GM & Director of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 2006. Mr. Huang served as President...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jin Ming Huang	GM & Director	4.9yrs	CN¥601.70k	keine Daten
Haipeng Yang	Chief Accountant & Director	no data	CN¥529.50k	keine Daten
Cong Sheng Liu	Deputy GM & Director	no data	CN¥529.50k	keine Daten
Jin Cheng Chen	Chairman of the Supervisory Committee	2yrs	CN¥207.60k	keine Daten
Jianjun Jia	Independent Director	6.8yrs	CN¥80.00k	keine Daten
Dong Ming Hong	Director	no data	CN¥444.50k	keine Daten
Guang Pei Li	Independent Director	6.8yrs	CN¥80.00k	keine Daten
Zhi Peng Fan	Independent Director	6.3yrs	CN¥80.00k	keine Daten
Tengyun Wei	Supervisor	2.4yrs	keine Daten	keine Daten
Hong Kai Xu	Member of the Supervisory Board	6.8yrs	keine Daten	keine Daten
Shouying Du	Independent Director	2.4yrs	CN¥80.00k	keine Daten
Huang Yalong	Employee Supervisor	2.4yrs	keine Daten	keine Daten

4.9yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 600436Die Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).

Zhangzhou Pientzehuang Pharmaceutical Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2024 Results on Apr 20, 2024

Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price

Full year 2023 earnings released: EPS: CN¥4.61 (vs CN¥4.10 in FY 2022)

Now 21% undervalued after recent price drop

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2023 Results on Oct 21, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥1.26 (vs CN¥1.04 in 2Q 2022)

Investor sentiment improves as stock rises 15%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.1% to CN¥302

Full year 2022 earnings released: EPS: CN¥4.09 (vs CN¥4.03 in FY 2021)

Less than half of directors are independent

Price target decreased to CN¥331

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: CN¥1.22 (vs CN¥1.48 in 3Q 2021)

Now 21% undervalued after recent price drop

Price target increased to CN¥380

Price target decreased to CN¥389

Price target decreased to CN¥389

First quarter 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to CN¥460

Now 23% undervalued after recent price drop

Price target increased to CN¥435

Third quarter 2021 earnings released: EPS CN¥1.48 (vs CN¥0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

Price target increased to CN¥281

First quarter 2021 earnings released: EPS CN¥0.94 (vs CN¥0.78 in 1Q 2020)

Price target raised to CN¥315

New 90-day high: CN¥326

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥2.76

New 90-day high: CN¥300

Price target raised to CN¥269

New 90-day high: CN¥252

New 90-day low: CN¥212

Third quarter earnings released

Annual earnings released: Earnings beat expectations

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high - CN¥208

Earnings released

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire 29.2% stake in Longhui Pharmaceutical Co., Ltd. from Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd.

Price target raised to CN¥163

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2020 Results on Aug 22, 2020

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter